GSK Prepares For Malaria Vaccine Roll-Out In Africa By 2015
This article was originally published in PharmAsia News
“While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive,” GSK CEO Witty says.
You may also be interested in...
At the organization’s Research and Hope Awards, the academics won for products that are already on the market, and the pharmaceutical company won for the vaccine that’s still in development.
Agenus will have sufficient cash to last through 2013 as it focuses on furthering its immunotherapeutics, including HerpV for genital herpes and Prophage Series G vaccines for glioma.
In another effort to boost development of malaria medicines GlaxoSmithKline is providing free public access to its library of 13,500 compounds that have shown some activity against the disease